EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

The Montana House of Representatives on Wednesday voted overwhelmingly against House Bill 371, a measure that would have banned mRNA vaccines — used primarily in COVID-19 vaccines and booster shots — ...

Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...

Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

The postponed ACIP meeting comes barely a week after Robert F. Kennedy, Jr. was confirmed as Secretary of Health and Human ...

The S&P 500 plunged by 1.7% on Friday, Feb. 21, as weak economic data and earnings forecasts sent the benchmark index lower for the second straight session.

In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to ...